Uwe Trefzer

10.7k total citations · 1 hit paper
78 papers, 4.5k citations indexed

About

Uwe Trefzer is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Uwe Trefzer has authored 78 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 42 papers in Oncology and 28 papers in Immunology. Recurrent topics in Uwe Trefzer's work include Immunotherapy and Immune Responses (23 papers), Melanoma and MAPK Pathways (22 papers) and CAR-T cell therapy research (20 papers). Uwe Trefzer is often cited by papers focused on Immunotherapy and Immune Responses (23 papers), Melanoma and MAPK Pathways (22 papers) and CAR-T cell therapy research (20 papers). Uwe Trefzer collaborates with scholars based in Germany, United States and Switzerland. Uwe Trefzer's co-authors include Dirk Schadendorf, Peter Hersey, Wolfram Sterry, Claus Garbe, Caroline Robert, Reinhard Dummer, Peter Mohr, Peter Walden, John M. Kirkwood and Jessica C. Hassel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Uwe Trefzer

77 papers receiving 4.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

2012 1.1k citations Caroline Robert, Claus Garbe et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Uwe Trefzer	2.8k	2.7k	1.1k	385	341	78	4.5k
Peter Mohr	1.9k 0.7×	2.5k 0.9×	705 0.6×	695 1.8×	204 0.6×	119	3.7k
Zachary A. Cooper	2.6k 0.9×	2.6k 1.0×	1.3k 1.2×	473 1.2×	301 0.9×	77	4.8k
Ragini R. Kudchadkar	1.6k 0.6×	2.6k 1.0×	1.3k 1.2×	493 1.3×	130 0.4×	128	3.9k
Adriano Piris	1.8k 0.6×	2.0k 0.7×	606 0.6×	369 1.0×	200 0.6×	69	3.5k
Lauren E. Haydu	3.8k 1.3×	5.1k 1.9×	1.2k 1.1×	774 2.0×	453 1.3×	124	6.7k
Leslie A. Fecher	1.6k 0.6×	2.1k 0.8×	788 0.7×	351 0.9×	185 0.5×	49	3.2k
Paola Queirolo	3.0k 1.1×	5.3k 2.0×	2.5k 2.3×	951 2.5×	267 0.8×	233	7.3k
Thinle Chodon	3.3k 1.2×	3.2k 1.2×	1.4k 1.3×	422 1.1×	578 1.7×	33	5.2k
Zeynep Eroglu	1.2k 0.4×	2.8k 1.1×	1.1k 1.0×	557 1.4×	145 0.4×	124	3.7k
Jacob Schachter	3.0k 1.1×	6.5k 2.4×	3.0k 2.7×	857 2.2×	161 0.5×	189	8.4k

Countries citing papers authored by Uwe Trefzer

Since Specialization

Citations

This map shows the geographic impact of Uwe Trefzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Trefzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Trefzer more than expected).

Fields of papers citing papers by Uwe Trefzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe Trefzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Trefzer. The network helps show where Uwe Trefzer may publish in the future.

Co-authorship network of co-authors of Uwe Trefzer

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe Trefzer. A scholar is included among the top collaborators of Uwe Trefzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe Trefzer. Uwe Trefzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weide, Benjamin, Thomas Eigentler, Chiara Catania, et al.. (2019). A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology Immunotherapy. 68(9). 1547–1559. 41 indexed citations

Lear, John T., Michael R. Migden, Karl D. Lewis, et al.. (2017). Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study. Journal of the European Academy of Dermatology and Venereology. 32(3). 372–381. 137 indexed citations

Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations

Mohr, Peter, Ulrik Birgersson, Carola Berking, et al.. (2013). Electrical impedance spectroscopy as a potential adjunct diagnostic tool for cutaneous melanoma. Skin Research and Technology. 19(2). 75–83. 64 indexed citations

Jarius, Sven, Astrid Knobel, Kaspar Josche Streitberger, et al.. (2013). GABAB receptor antibodies in paraneoplastic cerebellar ataxia. Journal of Neuroimmunology. 256(1-2). 94–96. 52 indexed citations

Egberts, Friederike, Ralf Gutzmer, Selma Ugurel, et al.. (2011). Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology. 22(7). 1667–1674. 26 indexed citations

Schrama, David, Wiebke K. Peitsch, Marc Zapatka, et al.. (2011). Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma. Journal of Investigative Dermatology. 131(8). 1631–1638. 122 indexed citations

Hofmann, Maja A., et al.. (2011). Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. The Journal of Dermatology. 38(9). no–no. 13 indexed citations

Patel, Poulam M., Stefan Suciu, Laurent Mortier, et al.. (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer. 47(10). 1476–1483. 142 indexed citations

10.

Terhorst‐Molawi, Dorothea, Cornelia Radke, & Uwe Trefzer. (2010). Ultra-late recurrence of malignant melanoma after a disease-free interval of 41 years. Clinical and Experimental Dermatology. 35(3). e20–e21. 10 indexed citations

11.

Hofmann, Maja A., et al.. (2008). Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma. Journal of Immunotherapy. 31(5). 520–527. 119 indexed citations

12.

Eberle, Jürgen, et al.. (2007). Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches. Drug Resistance Updates. 10(6). 218–234. 88 indexed citations

13.

Braumann, Chris, Christoph A. Jacobi, Stephan Rogalla, et al.. (2007). The Tumor Suppressive Reagent Taurolidine Inhibits Growth of Malignant Melanoma—a Mouse Model. Journal of Surgical Research. 143(2). 372–378. 17 indexed citations

14.

Fecker, Lothar F., Christoph C. Geilen, Georgi Tchernev, et al.. (2006). Loss of Proapoptotic Bcl-2-Related Multidomain Proteins in Primary Melanomas Is Associated with Poor Prognosis. Journal of Investigative Dermatology. 126(6). 1366–1371. 55 indexed citations

15.

Houben, Roland, Barbara Michel, Claudia S. Vetter‐Kauczok, et al.. (2006). Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma. Journal of Investigative Dermatology. 126(5). 1135–1142. 46 indexed citations

16.

Maza, Sofiane, Matthias Taupitz, Kasra Taymoorian, et al.. (2006). Multimodal fusion imaging ensemble for targeted sentinel lymph node management: initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. European Journal of Nuclear Medicine and Molecular Imaging. 34(3). 378–383. 14 indexed citations

17.

Maza, Sofiane, Uwe Trefzer, Maja A. Hofmann, et al.. (2006). Impact of sentinel lymph node biopsy in patients with Merkel cell carcinoma: results of a prospective study and review of the literature. European Journal of Nuclear Medicine and Molecular Imaging. 33(4). 433–440. 74 indexed citations

18.

Trefzer, Uwe, et al.. (2003). Malignant Melanoma Arising in a Radiotherapy Field: Report of Two Cases and Review of the Literature. Dermatology. 206(3). 265–268. 11 indexed citations

19.

Hofmann, Udo, et al.. (2003). Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma. Melanoma Research. 13(5). 531–536. 60 indexed citations

20.

Farzaneh, Farzin, Uwe Trefzer, Wolfram Sterry, & Peter Walden. (1998). Gene therapy of cancer. Immunology Today. 19(7). 294–296. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact